Cross species single domain antibodies targeting mesothelin for treating solid tumors

US12180296B2 · kind B2 · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Mitchell Ho · Urbana, US
• Ira H. Pastan · Potomac, US
• Jessica D. Hong · Herndon, US
• Nan Li · Tianjin, CN

Key dates

• Filing date: Jan 2, 2020
• Grant date: Dec 31, 2024
• Expiry date: Apr 28, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2510/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Camel single-domain monoclonal antibodies that specifically bind human and mouse mesothelin are described. Chimeric antigen receptor (CAR) T cells and antibody conjugates based on the mesothelin-specific antibodies are also described. The disclosed CAR T cells, mesothelin-specific antibodies and conjugates thereof can be used, for example, in the diagnosis or treatment of mesothelin-positive cancers.